Abstract
Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia. Follow-up has shown excellent response rates, progression-free survival, and overall survival after 8 years. However, some patients develop resistance to imatinib treatment because of a multitude of reasons. Strategies to overcome resistance include dose escalation of imatinib or switching to a second-generation tyrosine kinase inhibitor or to one of the newer non-tyrosine kinase inhibitors. This article guides the treating physician with a rational approach in the management of patients with chronic myeloid leukemia who fail initial treatment with imatinib or lose response while on therapy with imatinib.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 981-995 |
| Number of pages | 15 |
| Journal | Hematology/Oncology Clinics of North America |
| Volume | 25 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 2011 |
| Externally published | Yes |
Keywords
- Homoharringtonine
- Multikinase inhibitors
- Mutation screening
- Myeloproliferative disorders
- Tyrosine kinase inhibitors
ASJC Scopus subject areas
- Hematology
- Oncology
Fingerprint
Dive into the research topics of 'Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS